Caeli Nova
Innovative emergency oxygen systems for aviation, reducing flight times and carbon emissions.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | €7.7m | Series A | |
| Total Funding | 000k | ||
| GBP | 2021 | 2022 |
|---|---|---|
| Revenues | 0000 | 0000 |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
Caeli Nova is a pioneering company focused on developing advanced emergency oxygen systems for the aviation industry. Their flagship product, Cordillera, is an eagerly awaited update to traditional aircraft passenger emergency oxygen systems. Designed to allow safe overflight of challenging terrains such as the Himalayas on the L888 airway, Cordillera enables shorter flights and reduced operational costs for airlines. The company operates in the aerospace sector, serving commercial airlines and aircraft manufacturers. Caeli Nova's business model revolves around the research, development, and sale of cutting-edge aviation safety solutions. Revenue is generated through direct sales and strategic partnerships, such as their co-development agreement with Airbus. The company's agile R&D environment leverages medical research to innovate and enhance aviation safety.
Keywords: aviation, emergency oxygen systems, Cordillera, aerospace, airlines, Airbus partnership, safety, innovation, R&D, carbon emissions.